- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03635268
Endophthalmitis After Intravitreal Injection of Antiangiogenic Agents or Corticosteroids, a Cohort Study of the French Population of Patients Who Received Injections Over 9 Years (ENIVAC)
Intravitreal injections (IVI) of antiangiogenic agents (AA) have revolutionized the management of age-related macular degeneration (AMD) and diabetic macular edema (DME) in particular. Approximately 600,000 AA IVIs are performed each year in France.
Corticosteroid IVIs are an alternative in the treatment of macular edema when it is diabetic or related to venous occlusion, but also due to inflammation.
Endophthalmitis is one of the most feared complications after IVI because of its poor prognosis, despite its low incidence (values found in the literature between 0.01% and 0.08%). IVI practices have evolved over the years based on the recommendations of specialized organizations, with the current recommendation not to use antibiotic prophylaxis.
The purpose of this study is to study the effect of intravitreal injections of anti-angiogenic agents and corticosteroids on the occurrence of endophthalmitis within 28 days following an injection.
Study Overview
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- adult patients within the French population who had an intravitreal injection, identified by CCAM coding BGLB001
- associated with the delivery of an anti-angiogenic agent or a corticosteroid, identified by the corresponding CIP code
- between February 2007 and November 2015
Exclusion Criteria:
- intraocular surgery less than 42 days before the first injection, identified by the CCAM procedure
- risk factors for endogenous endophthalmitis identified in the 42 days preceding an IVI identified by the ICD10 code
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Frequency of occurrence of endophthalmitis
Time Frame: Up to 28 days following an intravitreal injection
|
Up to 28 days following an intravitreal injection
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MARIET AOI 2017
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intravitreal Injection
-
Mashhad University of Medical SciencesCompletedIntraocular Pressure Change in Intravitreal InjectionIran, Islamic Republic of
-
Illinois Retina AssociatesAlcon ResearchCompletedIntravitreal Injection PatientsUnited States
-
New York City Health and Hospitals CorporationCompletedPain | Intravitreal InjectionUnited States
-
Wolfson Medical CenterCompletedPain | Intravitreal Injection | Subconjunctival HemorrhageIsrael
-
Shanghai General Hospital, Shanghai Jiao Tong University...Not yet recruitingTo Evaluate the Safety and Tolerability of Intravitreal Injection of LX109 in Patients With nAMD
-
Wills EyeCompletedPain | Pain, Acute | Intravitreal InjectionUnited States, Canada
-
Recens Medical, Inc.CompletedMacular Degeneration | Diabetic Macular Edema | Anesthesia, Local | Intravitreal InjectionUnited States
-
Hemera BiosciencesWithdrawnGeographic Atrophy | Dry Age-related Macular Degeneration | Gene Therapy | Intravitreal Injection
-
University of OklahomaCompletedAge-Related Macular Degeneration | Diabetic Macular Edema | Intravitreal Injection | Ocular Rinse | Cystoid Macular EdemaUnited States
-
Damascus UniversityCompletedCataract | Intravitreal Injection | Diabete Type 2 | Triamcinolone AcetonideSyrian Arab Republic
Clinical Trials on Data collection
-
Care Management PlusCompletedHealth Information Technology | Nurse Based Care ManagementUnited States
-
University Hospital, Basel, SwitzerlandRecruitingInfections With CPBSwitzerland
-
M.D. Anderson Cancer CenterUnknownPediatric CancerUnited States
-
GlaxoSmithKlineCompletedInfections, StreptococcalRomania, Slovenia, Poland, Lithuania, Estonia
-
GCS Ramsay Santé pour l'Enseignement et la RechercheNot yet recruiting
-
Assistance Publique - Hôpitaux de ParisRecruiting
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Women and Infants Hospital of Rhode IslandTerminated
-
Centre Hospitalier Universitaire DijonCompletedCoronary Artery Bypass Graft | Anomalies in Glucose MetabolismFrance